Formulation design, preparation, and in vitro and in vivo characterizations of β-elemene-loaded nanostructured lipid carriers

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 2533-2541

  Shi, Feng ^a   Yang, Gang ^a   Ren, Juan ^b   Guo, Teng ^a   Du, Yan ^a   Feng, Nianping ^a  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

elemene; Anti tumor efficacy; High pressure homogenization; Nanostructured lipid carriers; Venous irritation

Indexed keywords

BETA ELEMENE; FLUOROURACIL; GLYCEROL STEARATE; NANOCARRIER; NANOSTRUCTURED LIPID CARRIER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DESIGN; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG SAFETY; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; NONHUMAN; PARTICLE SIZE; PLASMA CONCENTRATION-TIME CURVE; RABBIT; SOLID TUMOR; VASCULAR DISEASE; VASCULAR IRRITATION; X RAY DIFFRACTION; ZETA POTENTIAL;

Β-ELEMENE; ANTI-TUMOR EFFICACY; HIGH-PRESSURE HOMOGENIZATION; NANOSTRUCTURED LIPID CARRIERS; VENOUS IRRITATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG CARRIERS; LIPIDS; MICE; NANOPARTICLES; NANOTECHNOLOGY; PARTICLE SIZE; PRESSURE; RABBITS; RATS; RATS, WISTAR; SESQUITERPENES; VEINS;

EID: 84880581954     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S46578     Document Type: Article

References (35)

1. Ajazuddin, Saraf S. Applications of novel drug delivery system for herbal formulations. Fitoterapia. 2010;81(7):680-689.
2. Liu D, Liu Z, Wang L, Zhang C, Zhang N. Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel. Colloids Surf B Biointerfaces. 2011;85(2):262-269.
3. Lønning PE. Study of suboptimum treatment response: lessons from breast cancer. Lancet Oncol. 2003;4(3):177-185.
4. Li DC, Zhong XK, Zeng ZP, et al. Application of targeted drug delivery system in Chinese medicine. J Control Release. 2009;138(2):103-112.
5. Tian BC, Zhang WJ, Xu HM, et al. Further investigation of nanostructured lipid carriers as an ocular delivery system: in vivo transcorneal mechanism and in vitro release study. Colloids Surf B Biointerfaces. 2013;102:251-256.
6. Patlolla RR, Chougule M, Patel AR, Jackson T, Tata PN, Singh M. Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers. J Control Release. 2010;144(2):233-241.
7. Zhang WL, Gu X, Bai H, Yang RH, Dong CD, Liu JP. Nanostructured lipid carriers constituted from high-density lipoprotein components for delivery of a lipophilic cardiovascular drug. Int J Pharm. 2010;391(1-2):313-321.
8. Tiwari R, Pathak K. Nanostructured lipid carrier versus solid lipid nanoparticles of simvastatin: comparative analysis of characteristics, pharmacokinetics and tissue uptake. Int J Pharm. 2011;415(1-2):232-243.
9. Zhang R, Tian A, Zhang H, Zhou Z, Yu H, Chen L. Amelioration of experimental autoimmune encephalo?-elemene treatment is associated with Th17 and Treg cell balance. J Mol Neurosci. 2011;44(1):31-40.
10. Bao F, Qiu J, Zhang H. Potential role of β-elemene on histone H1 in the H22 ascites hepatpma cell line. Mol Med Report. 2012;6(1): 185-190.
11. Peng X, Zhao Y, Liang X, et al. Assessing the quality of RCTs on the effect of beta-elemene, one ingredient of a Chinese herb, against malignant tumors. Contemp Clin Trials. 2006;27(1):70-82.
12. Zhao J, Li QQ, Zou B, et al. In vitro combination characterization of the new anticancer plant drug beta-elemene with taxanes against human lung carcinoma. Int J Oncol. 2007;31(2):241-252.
13. Wang G, Li X, Huang F, et al. Antitumor effect of beta-elemene in non-small-cell lung cancer cells is mediated via induction of cell cycle arrest and apoptotic cell death. Cell Mol Life Sci. 2005;62(7-8): 881-893.
14. Chen ZH, Song YX, Che JJ, et al. Validation of a sensitive gas chromatographic-mass spectrometric method for the simultaneous determination of β-elemene and β-elemenal in human plasma. J Chromatogr B. 2009;877(4):408-414.
15. Sun YH, Liu GF, Zhang YQ, Zhu H, Ren YF, Shen YM. Synthesis and in vitro anti-proliferative activity of beta-elemene monosubstituted derivatives in HeLa cells mediated through arrest of cell cycle at the G1 phase. Bioorg Med Chem. 2009;17(3):1118-1124.
16. Zhang XY, Deng YJ, Zhao CJ, Wang XM, Li Z, Gao XF. [Study on pharmacokinetics of PVP coated beta-elemene liposome in rats]. Zhong Yao Cai. 2006;29(2):157-160. Chinese.
17. Liu Y, Wang P, Sun C, et al. Wheat germ agglutinin-grafted lipid nanoparticles: preparation and in vitro evaluation of the association with Caco-2 monolayers. Int J Pharm. 2010;397(1-2):155-163.
18. Zhuang CY, Li N, Wang M, et al. Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability. Int J Pharm. 2010;394(1-2):179-185.
19. Hu FQ, Jiang SP, Du YZ, Yuan H, Ye YQ, Zeng S. Preparation and characteristics of monostearin nanostructured lipid carriers. Int J Pharm. 2006;314(1):83-89.
20. Li J, Nie S, Yang X, Wang C, Cui S, Pan W. Optimization of tocol emulsions for the intravenous delivery of clarithromycin. Int J Pharm. 2008;356(1-2):282-290.
21. Shi F, Zhao JH, Liu Y, Wang Z, Zhang YT, Feng NP. Preparation and characterization of solid lipid nanoparticles loaded with frankincense and myrrh oil. Int J Nanomedicine. 2012;7:2033-2043.
22. Siekmann B, Westesen K. Melt-homogenized solid lipid nanoparticles stabilized by the nonionic surfactant tyloxapol. I. Preparation and particle size determination. Pharm Pharmacol Lett. 1994;3:194-197.
23. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm. 2000;50(1):161-177.
24. Guo CY, Yang CF, Li QL, et al. Development of a Quercetin-loaded nanostructured lipid carrier formulation for topical delivery. Int J Pharm. 2012;430(1-2):292-298.
25. Elsie O, Tiwari SB, Udupa N. Niosome entrapped β-cyclodextrin methotrexate complex as a drug delivery system. Int J Pharm. 1999;31(4):279-284.
26. Teeranachaideekul V, Souto EB, Junyaprasert VB, Müller RH. Cetyl palmitate-based NLC for topical delivery of Coenzyme Q(10) - development, physicochemical characterization and in vitro release studies. Eur J Pharm Biopharm. 2007;67(1):141-148.
27. Müller RH. [Zeta potential and particle charge in laboratory practice.] Zetapotential und Partikelladung in der Laborpraxis. Stuttgart: Wissenschaftliche Verlagsgesellschaft; 1996. German.
28. Westesen K, Siekmann B, Koch MHJ. Investigation on the physical state of lipid nanoparticles by synchrotron X-ray diffraction. Int J Pharm. 1993;93(1-3):189-199.
29. Yoh K, Niho S, Goto K, et al. Randomized trial of drip infusion versus bolus injection of vinorelbine for the control of local venous toxicity. Lung Cancer. 2007;55(3):337-341.
30. Wang Y, Mesfin GM, Rodríguez CA, et al. Venous irritation, pharmacokinetics, and tissue distribution of tirilazad in rats following intravenous administration of a novel supersaturated submicron lipid emulsion. Pharm Res. 1999;16(6):930-938.
31. Su M, Zhao M, Luo Y, et al. Evaluation of the efficacy, toxicity and safety of vinorelbine incorporated in a lipid emulsion. Int J Pharm. 2011;411(1-2):188-196.
32. Zhang HY, Tang X, Li HY, Liu XL. A lipid microsphere vehicle for vinorelbine: Stability, safety and pharmacokinetics. Int J Pharm. 2008;348(1-2):70-79.
33. Gao ZW, Zhang DL, Guo CB. Paclitaxel efficacy is increased by parthenolide via nuclear factor-kappaB pathways in in vitro and in vivo human non-small cell lung cancer models. Curr Cancer Drug Targets. 2010;10(7):705-715.
34. Feng L, Jia XB, Shi F, Chen Y. Identification of two polysaccharides from Prunella vulgaris L. and evaluation on their anti-lung adenocarcinoma activity. Molecules. 2010;15(8):5093-5103.
35. Morille M, Montier T, Legras P, et al. Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting. Biomaterials. 2010;31(2):321-329.